Chronic citalopram treatment induces time-dependent changes in the expression and DNA-binding activity of transcription factor AP-2 in rat brain

European Neuropsychopharmacology

Volumn 13, Issue 1, 2003, Pages 11-17

  Berggard C ^a   Damberg, M ^a   Oreland, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affective disorders; Antidepressants; Gene expression; Neuropharmacology; Serotonin

Indexed keywords

CITALOPRAM; ISOPROTEIN; TRANSCRIPTION FACTOR AP 2;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; MALE; MOLECULAR MECHANICS; MONOAMINERGIC SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RAT; TIME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CITALOPRAM; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; MALE; NUCLEAR PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS;

EID: 0037212061     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00075-5     Document Type: Article

References (32)

1. Benmansour S., Cecchi M., Morilak D.A., Gerhardt G.A., Javors M.A., Gould G.G., Frazer A. Effects of chronic antidepressant treatments on serotonin transporter function density and mRNA level. J. Neurosci. 19:1999;10494-10501.
2. Blier P., de Montigny C. Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J. Neurosci. 3:1983;1270-1278.
3. Blier P., de Montigny C., Tardiff D. Effects of the two antidepressant drugs mianserin and indalpine on the serotonergic system: single-cell studies in the rat. Psychopharmacology (Berlin). 84:1984;242-249.
4. Bosher J.M., Totty N.F., Hsuan J.J., Williams T., Hurst H.C. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene. 13:1996;1701-1707.
5. Bradely C.C., Blakely R.D. Alternative splicing of the human serotonin transporter gene. J. Neurochem. 69:(4):1997;1356-1367.
6. Butt T.R., Karathanasis S.K. Transcription factors as drug targets: opportunities for therapeutic selectivity. Gene Express. 4:1995;319-336.
7. Chaput Y., de Montigny C., Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electophysiological studies in the rat brain. Naunyn-Schmideberg's Arch Pharmacol. 333:1986;342-348.
8. Damberg M., Ekblom J., Oreland L. Chronic pharmacological treatment with certain antidepressants alters the expression and DNA-binding activity of transcription factor AP-2. Life Sci. 68:2000;669-678.
9. Damberg M., Eller M., Tõnissaar M., Oreland L., Harro J. Levels of transcription factors AP-2α and AP-2β in the brainstem are correlated to monoamine levels in the rat forebrain. Neurosci Lett. 313:2001;102-104.
10. Damberg M., Garpenstrand H., Hallman J., Oreland L. Genetic mechanisms of behaviour - don't forget about the transcription factors. Mol Psychiatry. 6:(5):2001;503-510.
11. Du Y.L., Wilcox B.D., Teitler M., Jeffrey J.J. Isolation and characterization of the rat 5-hydroxitryptamine type 2 receptor promoter: constitutive and inducible activity in myometrial smooth muscle cells. Mol Pharmacol. 45:(6):1994;1125-1131.
12. Emery J.G., Ohlstein E.H., Jaye M. Therapeutic modulation of transcription factor activity. Trends Pharmacol. Sci. 22:2001;233-240.
13. Greco D., Zellmer E., Zhang Z., Lewis E. Transcription factor AP-2 regulates expression of the dopamine β-hydroxylase gene. J. Neurochem. 65:(2):1995;510-516.
14. Hahn S.L., Hahn M., Kang U.J., Joh T.H. Structure of the rat aromatic L-amino acid decarboxylase gene: evidence for an alternative promoter usage. J. Neurochem. 60:(3):1993;1058-1064.
15. Healy D.P., O'Rourke D.A. Regulation of dopamine-1A (D1A) receptor gene transcription. Clin. Exp. Hypertens. 19:(1/2):1997;1-13.
16. Heguy A., Stewart A.A., Haley J.D., Smith D.E., Foulkes J.G. Gene expression as a target for new drug discovery. Gene Express. 4:1995;337-344.
17. Heils A., Wichems C., Mössner R., Petri S., Glatz K., Bengel D., Murphy D.L., Lesch K.P. Functional characterization of the murine serotonin transporter gene promoter in serotonergic raphe neurons. J. Neurochem. 70:1998;932-939.
18. Kobayashi K., Kurosawa Y., Fujita K., Nagatsu T. Dopamine β-hydroxylase gene: two mRNA types having different 3′-terminal regions are produced through alternative polyadenylation. Nucleic Acids Res. 17:(3):1989;1089-1102.
19. Lesch K.P., Heils A. Serotonergic gene transcriptional control regions: targets for antidepressant drug development? Int. J. Neuropsychopharmacol. 3:2000;67-79.
20. Lowry O.H., Rosbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:(265):1951;265-275.
21. McMahon M., Sabban E. Regulation of expression of dopamine β-hydroxylase in PC12 cells by glucocorticoids and cyclic AMP analogues. J. Neurochem. 59:(6):1992;2040-2047.
22. Meaney M.J., Diorio J., Francis D., Weaver S., Yau J., Chapman K., Seckl J.R. Postnatal handling increases the expression of cAMP-inducible transcription factors in the rat hippocampus: the effects of thyroid hormones and serotonin. J. Neurosci. 20:(10):2000;3926-3935.
23. Mitchell P.J., Timmons P.M., Herbert J.M., Rigby P.W., Tjian R. Transcription factor AP-2 is expressed in neural crest lineages during mouse embryogenesis. Genes Dev. 5:1991;105-119.
24. Moser M., Rüschoff J., Buettner R. Comparative analysis of AP-2α and AP-2β gene expression during murine embryogenesis. Dev. Dyn. 208:1997;115-124.
25. 1BmRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology. 15:(5):1996;515-522.
26. Olsson T., Håkansson A., Seckl J.R. Ketanserin selectively blocks acute stress-induced changes in NGFI-A and mineralcorticoid receptor gene expression in hippocampal neurons. Neuroscience. 76:(2):1997;441-448.
27. Olsson T., Mohammed A.K., Donaldson L.F., Seckl J.R. Transcription factor AP-2 gene expression in adult rat hippocampal regions: effects of environmental manipulations. Neurosci. Lett. 189:1995;113-116.
28. Papavassiliou A.G. Transcription-factor-modulating agents: precision and selectivity in drug design. Mol. Med. Today. 4:(8):1998;358-366.
29. Pineyro G., Blier P., Dennis T., de Montigny C. Desentization of the neuronal 5-HT carrier following its long-term blockade. J. Neurosci. 14:1994;3036-3044.
30. Roesler W.J., Vandenbark G.R., Hanson R.W. Cyclic AMP and the induction of eukaryotic gene transcription. J. Biol. Chem. 263:(19):1988;9063-9066.
31. Williams T., Tjian R. Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. Genes Dev. 5:1991;670-682.
32. Williams T., Tjian R. Characterization of a dimerization motif in AP-2 and its function in heterologous DNA binding proteins. Science. 251:(4997):1991;1067-1071.